ELEVAI LABS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.579 USD | -1.03% |
|
-1.86% | -68.33% |
| 06-14 | Elevai Labs Inc. Forms New Scientific Advisory Board | CI |
| 05-19 | Certain Common Stock of Elevai Labs, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. | CI |
| Sales 2022 | 0.77 60.48 | Sales 2023 | 1.71 135.17 | Capitalization | 31.68M 2.5B |
|---|---|---|---|---|---|
| Net income 2022 | -1M -78.93M | Net income 2023 | -4M -316M | EV / Sales 2022 * | - |
| Net cash position 2022 | 872K 68.8M | Net cash position 2023 | 3.12M 246M | EV / Sales 2023 | 16,679,740 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-4.57
x | Employees | 18 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 19.59% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.03% | ||
| 1 week | -1.86% | ||
| Current month | -12.27% | ||
| 1 month | -13.34% | ||
| 3 months | -17.52% | ||
| 6 months | -68.36% | ||
| Current year | -68.33% |
1 week
0.57
0.61
1 month
0.570.69
Current year
0.573.89
1 year
0.574.24
3 years
0.574.24
5 years
0.574.24
10 years
0.574.24
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/06/24 | 0.579 | -1.03% | 30,895 |
| 24/06/24 | 0.585 | +0.86% | 26,820 |
| 21/06/24 | 0.58 | -1.53% | 24,720 |
| 20/06/24 | 0.589 | -0.17% | 48,331 |
| 18/06/24 | 0.59 | -1.17% | 60,846 |
Delayed Quote Nasdaq, June 25, 2024 at 09:30 pm
More quotes
Elevai Labs, Inc. is a physician-dispensed skincare company. The Company conducts research and development to advance science-driven topical skincare that complements the medical aesthetics industry. It produces and commercializes topical skincare products that contain its proprietary stem cell derived Elevai Exosomes designed to enhance the appearance of skin. Its Precision Regenerative Exosome Technology (PREx) biotechnology process yields exosome lots from human umbilical cord-derived mesenchymal stem cells (hUMSC) for its specialty physician-dispensed skincare product lines. It has integrated the use of stem cell exosomes into its initial product line: Elevai Post Treatment E-Series. The E-Series comprises two post-skincare procedure care products that target the face and neck, and upper chest regions. Its products include Empower and Enfinity serums. Empower is its after-treatment topical product that supports the appearance of healthy skin and promotes an even toned complexion.
| 1st Jan change | Capi. | |
|---|---|---|
| -68.33% | 10.94M | |
| +38.36% | 52.73B | |
| +38.87% | 39B | |
| -8.63% | 38.52B | |
| +25.46% | 30.38B | |
| -11.17% | 26.39B | |
| +11.44% | 26.08B | |
| +45.09% | 14.15B | |
| +32.93% | 12.6B | |
| -5.30% | 11.51B |
- Stock Market
- Equities
- ELAB Stock
